

# Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

## MUTZ-3

RRID:CVCL\_1433

Type: Cell Line

### Proper Citation

RRID:CVCL\_1433

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_1433](https://web.expasy.org/cellosaurus/CVCL_1433)

**Proper Citation:** RRID:CVCL\_1433

**Description:** Cell line MUTZ-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Acute myeloid leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2) GATA2, MECOM

**Defining Citation:** [PMID:8667638](#), [PMID:9096695](#), [PMID:12091369](#), [PMID:16408098](#), [PMID:16423051](#), [PMID:17533051](#), [PMID:26252775](#), [PMID:26589293](#), [PMID:26764012](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:36982453](#)

**Comments:** Characteristics: Can be differentiated into interstitial DC-like cells by stimulation with CSF2, IL4 and TNF (PubMed=26252775)., Characteristics: Contains both CD34+ stem cell and CD14+ monocyte/macrophage cell populations and can thus be considered as a hematopoietic progenitor/stem cell line. Can differentiate into an osteoclast (OC)-like lineage (PubMed=17533051)., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** MUTZ-3

**Synonyms:** Mutz-3, MUTZ3, Mutz3, Menschliche Und Tierische Zellkulture-3

**Cross References:** CLO:CLO\_0007903, EFO:EFO\_0005395, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722,

BioSample:SAMN03473344, BioSample:SAMN10989596, cancercellines:CVCL\_1433, Cell\_Model\_Passport:SIDM01873, Cosmic:787462, Cosmic:975281, Cosmic:1012102, Cosmic:1281338, Cosmic:2306224, Cosmic:2378088, Cosmic:2733530, DepMap:ACH-000084, DSMZ:ACC-295, DSMZCellDive:ACC-295, GEO:GSM305093, GEO:GSM305094, GEO:GSM305095, GEO:GSM801964, GEO:GSM1374693, GEO:GSM2037138, GEO:GSM2037139, LiGeA:CCLE\_080, Lonza:53, Pharmacodb:MUTZ3\_970\_2019, PRIDE:PXD002951, Wikidata:Q54907100

**ID:** CVCL\_1433

**Record Creation Time:** 20220427T220828+0000

**Record Last Update:** 20260905T181223+0000

---

## Ratings and Alerts

No rating or validation information has been found for MUTZ-3.

No alerts have been found for MUTZ-3.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 7 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Birdwell CE, et al. (2025) BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. Leukemia.

Birdwell CE, et al. (2024) Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia, 38(3), 545.

Huang Y, et al. (2022) Annexin A2: The diversity of pathological effects in tumorigenesis and immune response. International journal of cancer, 151(4), 497.

Smeenk L, et al. (2021) Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia. Cancer discovery, 11(11), 2868.

Riedel SS, et al. (2021) Intrinsically disordered Meningioma-1 stabilizes the BAF complex to cause AML. Molecular cell, 81(11), 2332.

Jackson R, et al. (2020) The Potentials and Pitfalls of a Human Cervical Organoid Model Including Langerhans Cells. Viruses, 12(12).

van Galen P, et al. (2019) Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell, 176(6), 1265.